Switching from the adalimumab originator to biosimilar SB5 (Imraldi) appears to be safe and effective in our study with >12m followup Charlie Lees Spyros Siakavellas Laura Lucaciu Nikolas Plevris Mathew Lyons Nathan Constantine-Cooke Phil Jenkinson Gareth-Rhys Jones #DDW2021 eposters.ddw.org/ddw/2021/ddw-2…

We reported our experience with adalimumab biosimilar SB5 in the Edinburgh IBD unit SB5 appeared to be safe & effective in >12m FUP Effectiveness and Safety of Adalimumab Biosimilar SB5 in IBD: Outcomes in Originator to SB5 Switch, Double Biosimil… pubmed.ncbi.nlm.nih.gov/34089587/

Registration is now live Link to register below 👇 In person or virtual

2 weeks to go - Thursday 13th January Do not miss out - register now and join us live. Featuring PREDICT IBD Kevin Whelan Jeffrey Barrett Bram Verstockt Nikolas Plevris Tim Raine Robin Dart Laura Fachal Laurie Keefer, PhD NickPowellLab Tariq Ahmad CLARITY IBD

Are you excited for IBD Edinburgh 2022? Listen to this brief message from Nikolas Plevris who is talking on “Monitoring IBD: setting thresholds for decision making”

Out today open access in AP&T, we describe 10 years of hospital admissions for IBD patients from the Lothian IBD Registry in Edinburgh. doi.org/10.1111/apt.16… Key findings... a🧵 Gareth-Rhys Jones Charlie Lees Lauranne Derikx Nikolas Plevris NHS Lothian Edinburgh Medical School

We reported our experience with UST in the Edinburgh IBD unit 1/3 of CD patients underwent UST dose intensification to 4- or 6-weekly <1y Risk factors for dose intensification: - Anti-TNF and Vedo failure - corticosteroid use at UST initiation Charlie Lees 🧵👇

In times of ⏫healthcare💰, check this out: N=297 IBD 🏴󠁧󠁢󠁳󠁣󠁴󠁿 Multiple IFX originator to biosimilars switches demonstrated comparable: 1⃣ Clinical remission 2⃣ Biochemical (CRP) remission 3⃣ Faecal calprotectine values ➡️This will help reduce💰! UEGJ 🔜 to be published🔥

This 🙌

Phenomenal resource created by the superstar that is Beatriz Gros. Always striving to improve the care of IBD patients worldwide!

Multiple successive switches from IFX originator to biosimilars are effective and safe in patients with IBD, irrespective of the number of IFX switches. 🧵 Our paper is open for you to read. onlinelibrary.wiley.com/doi/full/10.10…

Not at #ECCO23 this year? This is our poster in which we identify distinctive faecal calprotectin profiles in IBD with over 2400 subjects (WIP, subject to change). We are looking for collaborators for validation/external cohorts! Interested? Please contact me or Charlie Lees.

Happy to announce our #IBD research, in which we use faecal calprotectin over time to characterise Crohn's disease heterogeneity, is now available as an article in press with CGH! (Open access and proofed versions to follow at a later date) cghjournal.org/article/S1542-…

See you soon Chicago! 🤓🤝🍕🌭🏙 #DDW2023 #DDW23

The author-corrected version of our CGH paper is now available (open access)! doi.org/10.1016/j.cgh.…

One of the best courses I have been on! Fantastic weekend, in beautiful Luneburg, learning new skills to help improve the care of our patients living with IBD. InternationalBowelUS #IUS

Cross disciplinary team effort 💪🏽Drs Iona Campbell& Michael Glinka, Fadlo Shaban, DrsKate Kirkwood & Francesca Nadalin David Adams Mark Arends Irene Papatheodorou - Ειρήνη Παπαθεοδώρου Profs Baldock & Burger. 🙌🏽All the amazing & incredibly talented people who make this possible.

I’ve been working with the British Society for Immunology (BSI) to develop a new online training course on IBD immunology in clinical practice. The first gastroenterology day is on 5th June; details 👉bit.ly/3x2jEEV BSI Congress & Events JimBrewer Nikolas Plevris Beatriz Gros

Upadacitinib for Crohn's disease • data from Edinburgh and Exeter • n=93 with median 25w follow-up • effective in highly refractory cohort See 👇 for figures and link Frontline Gastro

Check out latest study by Elford et al. on the real-world effectiveness of Upadacitinib in Crohn's disease. Their findings underscore Upa as a promising rx option for medically refractory CD link: bit.ly/4aMZSvJ Alex Elford, Nikolas Plevris, Nick Kennedy Mohsen Subhani